Letter to shareholders 2006

This document is important and requires your immediate attention. If you are in any doubt as to what action you should take, you should consult your stockbroker, bank manager, solicitor, accountant or other professional advisor immediately.

23rd March 2006
To the holders of the company’s Ordinary Shares and American Depositary Shares and, for information, to the holders of the SmithKline Beecham plc Floating Rate Unsecured Loan Stock.

Dear Shareholder,

Annual General Meeting 2006
I am pleased to enclose the Notice of Meeting for the sixth Annual General Meeting (‘AGM’) of GlaxoSmithKline plc. The AGM will be held at 2.30pm on Wednesday, 17th May 2006 at the Queen Elizabeth II Conference Centre, Broad Sanctuary, Westminster, London SW1.

If you will not be attending you may wish to appoint a proxy electronically via www.shareview.co.uk or www.sharevote.co.uk or if you hold your shares in CREST via the CREST system or by completing and returning the enclosed form of proxy. In each case notice of your appointment of a proxy should reach the company’s registrar no later than 2.30pm on Monday, 15th May 2006.

The Annual Review enclosed contains summary Financial Statements for the year to 31st December 2005. A copy of the Annual Report is also enclosed for those who have requested a copy. A resolution referring to the Financial Statements is included in the ordinary business of the AGM. In addition, resolutions are proposed covering the election of Dr Moncef Slaoui, who will succeed Dr Yamada as Chairman of Research & Development, and Mr Tom de Swaan. Our Articles of Association require that every year a proportion of our current Directors must retire by rotation. I therefore ask you to support the re-election of Mr Larry Culp, Sir Crispin Davis and Dr Ronaldo Schmitz who will each retire and offer themselves for re-election. Explanatory notes for all the business of the AGM are given on pages 4 and 5 of this document.

Recommendation
Your Board believes that the resolutions contained in the Notice of Meeting are in the best interests of the company and shareholders as a whole and recommends you to vote in favour of them, as your Directors intend to do in respect of their beneficial shareholdings.

Yours sincerely

Sir Christopher Gent
Chairman
GlaxoSmithKline